Dr. Eric K. Chin, MD

Dr. Chin practices at Advanced Pain Specialists of Southern California - HOPD in Riverside, California.

Dr. Chin's NPI, 1043442809, was assigned on August 12, 2009. Dr. Chin graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2009. Dr. Chin holds California license A114525.

Dr. Chin's primary practice is Advanced Pain Specialists of Southern California - HOPD, at 9041 Magnolia Ave, Riverside, CA 92503.

Dr. Chin's primary practice is Advanced Pain Specialists of Southern California - HOPD in Riverside, California. Dmand AI also links Dr. Chin to 2 group practices and clinics and 2 medical groups, each named with a free account. Dr. Chin's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chin practices, 3 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Chin's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Chin is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Chin's licenses on file in 3 states: California, Iowa and Illinois.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eyelid inflammation, glaucoma, hereditary corneal conditions and hypertensive retinopathy among the conditions Dr. Chin treats.

CMS data shows 24,246 Medicare services from Dr. Chin across 21 procedure codes in 2024, for 786 Medicare patients. Medicare paid $2,021,198 for them.

CMS counts 786 Medicare patients who saw Dr. Chin in 2024. The largest group is 75 to 84, with 293 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chin's median patient age at 69, with 54% women.

In 2024, Dr. Chin wrote 626 Medicare Part D claims for 190 patients. 62% of them were for generic drugs. CMS names the drug for 593 of them, across 9 drugs with 11 or more claims each, at $15,471 in total drug cost. In 2023, CMS named 575 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Chin for performance year 2024, reported as part of a group. Dr. Chin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 14 procedures of cataract surgery by Dr. Chin, more than 37% of the clinicians it reports for that procedure.

Dmand AI links 125 papers to Dr. Chin, published from 2008 to 2025. 2015 was the busiest year, with 12. The most frequent topics are Tomography, Optical Coherence, Visual Acuity and Vitrectomy. Dr. Chin has published most often in JAMA Ophthalmol. Dr. Chin's most frequent co-authors are David R. Almeida, MBA, MD, PhD, Vinit Bharati Mahajan, MD, PhD and Kunyong Xu, MD.

CMS Open Payments shows 182 general payments to Dr. Chin from 29 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 42% of the total. Genentech, Inc. paid the most, $2,739.

Dmand AI lists 14 awards for Dr. Chin, most recently Clinical Teaching Award in 2019.

Dr. Chin graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2009.

Dr. Chin is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.